EVO: Evotec SE - Summary | Jitta

Evotec SE

NASDAQ:EVO

Price
$9.63
Loss Chance
50.9%
3.09JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
600 / 1,157
3,760 / 5,055
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (40)
Recent Business Performance (29)
Financial Strength (53)
Return to Shareholders (7)
Competitive Advantage (42)
Jitta Signs
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Debt LevelVery High Long Term Debt
Recent Business PerformanceEarning decline 1334.29% in the last quarter (yoy)
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
3.09
100.00%
2.00
167.67%
Life Sciences Tools and Services
5.17
50.31%
6.70
18.59%
5.13
22.27%
COMPANY DESCRIPTION
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.